Industry

Phase 3 trial to study urcosimod in neuropathic corneal pain

Healio Optometry23h ago1 min read

The FDA favorably reviewed plans for a phase 3 trial of urcosimod, which is being investigated for the treatment of neuropathic corneal pain, according to a press release from Okyo Pharma.The feedback came during a meeting between Okyo Pharma and the FDA, paving the way for a pivotal trial in a disease that currently has no specifically approved treatments.“Neuropathic corneal pain remains one of the most challenging and underserved conditions in eye care, with patients often living with persistent pain,” Robert J. Dempsey, CEO of Okyo Pharma, told Healio.The trial, called

Read full article on Healio Optometry

AI Summary

Quick Take

Okyo Pharma is moving forward with a pivotal Phase 3 trial for urcosimod (OK-101) to treat neuropathic corneal pain following a favorable review of its study plans by the FDA. This investigational therapy aims to address a significant gap in the ophthalmic market, as there are currently no FDA-approved treatments specifically indicated for this debilitating condition.

Why It Matters

Neuropathic corneal pain (NCP) is a notoriously difficult-to-treat condition where patients experience chronic, often severe ocular pain that is frequently out of proportion to clinical signs of surface disease. Currently, clinicians are forced to manage these patients using off-label systemic neuromodulators, autologous serum, or palliative care, which often yield inconsistent results. A successful Phase 3 trial for urcosimod would provide the first validated pharmacological pathway for NCP, offering a targeted solution for a patient population that is often frustrated by the limitations of standard dry eye protocols.

Key Details

The FDA provided favorable feedback on the proposed Phase 3 trial design during a formal meeting with Okyo Pharma.
Urcosimod is being developed as a first-in-class treatment specifically for the persistent pain associated with neuropathic corneal conditions.
The upcoming study is designed as a pivotal trial, intended to provide the primary clinical evidence for a future New Drug Application (NDA).
The drug candidate, also known as OK-101, has previously been studied for its anti-inflammatory and analgesic properties in ocular surface disease.

Practice Implications

Clinicians should maintain a high index of suspicion for neuropathic components in patients who report persistent ocular burning or aching despite a relatively healthy-looking corneal surface. While this trial progresses, identifying these patients early is essential, as they may eventually become candidates for this targeted therapy if it receives regulatory approval.

Who's Affected

Cornea SpecialistsComprehensive OphthalmologistsOptometristsOcular Surface Disease Specialists

What's Next

Okyo Pharma will initiate the pivotal Phase 3 trial based on the FDA-reviewed protocol. Future updates are expected to detail the specific enrollment criteria and the timeline for the primary endpoint data readout.

Evidence StrengthModerate

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.